- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
- Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
- Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
- Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
- Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
- Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
- Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Acadia Announces Additions to Executive Team
More ▼
Key statistics
On Friday, ACADIA Pharmaceuticals Inc (ACAD:NSQ) closed at 16.82, 1.33% above its 52-week low of 16.60, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.98 |
---|---|
High | 17.30 |
Low | 16.62 |
Bid | 16.82 |
Offer | 17.30 |
Previous close | 17.07 |
Average volume | 1.48m |
---|---|
Shares outstanding | 164.77m |
Free float | 163.86m |
P/E (TTM) | -- |
Market cap | 2.77bn USD |
EPS (TTM) | -0.3774 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼